Naomi Logsdon is a molecular biologist and laboratory manager with over 30 years of experience and an outstanding record of scientific research in both academic and industrial settings. She is a co-author on more than 40 peer-reviewed publications and holds two gene patents.
Logsdon graduated from Rice University cum laude with a B.A. in Biology. She began her research as an undergraduate assistant and was co-author on four research publications studying oxygen radical toxicity. Cell biology and cancer were the focus at subsequent positions at Baylor College of Medicine, DuPont Merck Pharmaceuticals, and the University of Delaware. Protein expression and purification became an area of interest at AstraZeneca Pharmaceuticals, where she evaluated several expression systems for use in high-throughput screening. She also cloned two novel potassium channels as potential drug targets. She later joined the University of Alabama at Birmingham (UAB) at the Center for Biological Sciences and Engineering, where her protein expression and purification skills were applied to crystallographic studies of interleukins. She held managerial and technical positions in several other labs at UAB prior to joining TriAltus in 2019.